Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Novartis”

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial FibrillationRecruiting
NCT07217067Phase 2Updated Jul 31, 2026
Sponsor: Novartis Pharmaceuticals
Atrial Fibrillation
United States, Canada, China, Germany, Netherlands +2 more
DFT383 in Pediatric Participants With Nephropathic CystinosisRecruiting
NCT06910813Phase 1, Phase 2Updated Jul 31, 2026
Sponsor: Novartis Pharmaceuticals
Nephropathic Cystinosis
United States
A 24-week rPMS Study in Real-world Setting for EnerzairActive Not Recruiting
NCT05274425N/AUpdated Jul 31, 2026
Sponsor: Novartis Pharmaceuticals
Asthma
South Korea
Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AnticoagulationNot Yet Recruiting
NCT07739888Phase 3Updated Jul 31, 2026
Sponsor: Novartis Pharmaceuticals
Atrial Fibrillation (AF)
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 MutationsActive Not Recruiting
NCT04641442Phase 2Updated Jul 31, 2026
Sponsor: Novartis Pharmaceuticals
NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
United States, Czechia, France, Italy, Japan +2 more
Characterizing the Use of Ofatumumab in a Real World SettingCompleted
NCT05090033N/AUpdated Jul 31, 2026
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Australia
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaActive Not Recruiting
NCT03091257Phase 1Updated Jul 31, 2026
Sponsor: Massachusetts General Hospital
Multiple Myeloma
United States
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Recruiting
NCT07517263Phase 3Updated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Cardiovascular Disease and Lipoprotein(a)
United States, Argentina, Australia, Austria, Belgium +34 more
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VRecruiting
NCT05268289Phase 2Updated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Lupus Nephritis
United States, Argentina, Brazil, China, Colombia +15 more
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisRecruiting
NCT05344469N/AUpdated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Germany
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsRecruiting
NCT07288359Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Advanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Metastatic Castration-resistant Prostate Cancer
United States, Czechia, Denmark, France, Germany +5 more
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyActive Not Recruiting
NCT04557462Phase 3Updated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Primary IgA Nephropathy
United States, Argentina, Australia, Belgium, Brazil +30 more
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial CarcinomaCompleted
NCT01797523Phase 2Updated Jul 30, 2026
Sponsor: M.D. Anderson Cancer Center
Endometrial Cancer
United States
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant HypercholesterolemiaRecruiting
NCT07610278Phase 2Updated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Hypercholesterolaemia
United States
Long-term Follow up Local Registry Study of Kymriah in South KoreaRecruiting
NCT06785818N/AUpdated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
South Korea
A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi ArabiaNot Yet Recruiting
NCT07737756N/AUpdated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Spinal Muscular Atrophy
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's DiseaseNot Yet Recruiting
NCT07737743Phase 2Updated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Sjögren's Disease
A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)Not Yet Recruiting
NCT07737730N/AUpdated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Axial Spondyloarthritis · Ankylosing Spondylitis · Non-Radiographic Axial Spondyloarthritis
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceRecruiting
NCT06830720N/AUpdated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Breast Neoplasms
Austria, Germany
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.Recruiting
NCT07543120Phase 2Updated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Hypertension (HTN)
United States, Japan, Singapore
A Study of Alpelisib and Fulvestrant to Treat Endometrial CancerActive Not Recruiting
NCT05154487Phase 2Updated Jul 30, 2026
Sponsor: GOG Foundation
Endometroid Endometrial Cancer
United States
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular EdemaCompleted
NCT04543331N/AUpdated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration (nAMD) · Diabetic Macular Edema (DME)
Germany
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.Recruiting
NCT07140614Phase 1Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Charcot-Marie-Tooth Disease, Type 1A
Canada
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersRecruiting
NCT06562192Phase 1Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Pancreatic Ductal Adenocarcinoma · Non-small Cell Lung Cancer · HR+/HER2- Ductal and Lobular Breast Cancer · Triple Negative Breast Cancer
United States, Belgium, Canada, France, Germany +5 more
A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.Completed
NCT06431763Phase 4Updated Jul 29, 2026
Sponsor: Novartis Pharmaceuticals
Hypercholesterolemia
Germany

Previous page Next page